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OsteoclastsBone development is dependent on the functionality of three essential cell types: chondrocytes, osteoclasts and
osteoblasts. If any of these cell types is dysfunctional, a developmental bone phenotype can result.
The bone disease osteopetrosis is caused by osteoclast dysfunction or impaired osteoclastogenesis, leading to
increased bone mass. In ClC-7 deﬁcient mice, which display severe osteopetrosis, the osteoclast malfunction is
due to abrogated acidiﬁcation of the resorption lacuna. This study sought to investigate the consequences of
osteoclast malfunction on bone development, bone structure and bone modeling/remodeling in ClC-7 deﬁcient
mice. Bones from wildtype, heterozygous and ClC-7 deﬁcient mice were examined by bone histomorphometry
and immunohistochemistry.
ClC-7 deﬁcient mice were found to have a severe developmental bone phenotype, characterized by dramatically
increased bone mass, a high content of cartilage remnants, impaired longitudinal and radial growth, as well as
lack of compact cortical bone development. Indices of bone formation were reduced in ClC-7 deﬁcient mice;
however, calcein labeling indicated that mineralization occurred on most trabecular bone surfaces. Osteoid
deposition had great regional variance, but an osteopetrorickets phenotype, as observed in oc/oc mice, was not
apparent in theClC-7deﬁcientmice.A strikingﬁndingwas thepresenceof very large abnormal osteoclasts,which
ﬁlled the bonemarrow space within the ClC-7 deﬁcient bones. The development of these giant osteoclasts could
be due to altered cell fate of the ClC-7 deﬁcient osteoclasts, caused by increased cellular fusion and/or prolonged
osteoclast survival.
In summary, malfunctional ClC-7 deﬁcient osteoclasts led to a severe developmental bone phenotype including
abnormally large and non-functional osteoclasts. Bone formation paremeters were reduced; however, bone
formation and mineralization were found to be heterogenous and continuing.lev Hovedgade 207, DK-2730
sen).
al Surgery, Faculty of Dentistry,
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Bone development is an intricate process, which in long bones is
characterized by the formation of a cartilage model including both
mineralized and unmineralized cartilage, which is subsequently
degraded and replaced by bone matrix, a process called endochondral
ossiﬁcation (Baron, 2003). During endochondral ossiﬁcation, the
chondrocytes within the cartilage model become hypertrophic and
undergo apoptosis. This creates spaces within the cartilage model that
are invaded by the vascular system which supplies progenitor cells tothe developing bones (Baron, 2003; Mackie et al., 2008). In the process
of replacing the cartilagemodel with bone, perivascular and endothelial
cells (Schenk et al., 1967) as well as migrating osteoclasts (Blavier and
Delaisse, 1995; Engsig et al., 2000) degrade the unmineralized cartilage,
whereas cartilage-resorbing osteoclasts (chondroclasts) degrade the
mineralized cartilage matrix (Everts et al., 2009; Schenk et al., 1967;
Shibata et al., 1997). Osteoblasts subsequently form the new bone
matrix of the trabecular bone (Baron, 2003;Mackie et al., 2008). During
this type of bone development, a bone collar (formed by intramem-
braneous ossiﬁcation) is developed around the initial cartilage model,
andwill eventually develop into the cortical bone, constituting the outer
shell of the long bone (Baron, 2003). The process of long bone
development therefore requires functionality of at least three cell
types: chondrocytes for formation of the cartilagemodel, osteoclasts for
degradation of the mineralized cartilage matrix and osteoblasts for
formationof bonematrix (Baron, 2003;Mackie et al., 2008; Schenket al.,
1967; Shibata et al., 1997).
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compartments are continuously degraded and replaced by new bone
matrix by either modeling or remodeling throughout life (Clarke, 2008),
and the integrity of these two processes is of utmost importance for
normal bone homeostasis. The remodeling process, which predominates
over the modeling process in normal adult individuals (Clarke, 2008), is
characterized by a tight coupling between bone resorption and bone
formation (Karsdal et al., 2005; Martin, 1993; Martin and Rodan, 2001;
Sims and Gooi, 2008). This coupling ensures that equal amounts of bone
are being resorbed and subsequently formed tomaintain the status quo of
the bone mass (Martin, 1993; Martin and Rodan, 2001). Several lines of
investigation have indicated that the osteoclasts themselves contribute
strongly to the coupling process (Karsdal et al., 2005, 2007, 2008; Karsdal
andHenriksen, 2007;Martin et al., 2009;Martin and Rodan, 2001;Martin
and Sims, 2005; Pederson et al., 2008; Sims and Gooi, 2008).
Imbalance in coupling can lead to pathological conditions including
osteoporosis where bone resorption exceeds bone formation and a net
loss of bone occurs (Mundy et al., 2003). Conversely, in osteopetrosis
bone resorption is absent or low due to lacking or dysfunctional
osteoclasts, resulting in a pathologic bone phenotype comprising high
bone mass and lack of bone marrow space (Balemans et al., 2005;
Helfrich, 2003; Ogbureke et al., 2005; Segovia-Silvestre et al., 2009;
Teitelbaum, 2000; Tolar et al., 2004).
Osteoclast dysfunction results from mutations in several proteins
which are critical for the resorptionprocess (Segovia-Silvestre et al., 2009;
Tolar et al., 2004). In the majority of human cases defects in the genes
CLCN7 and TCIRG1, which encode the ClC-7 chloride channel and the a3
subunit of the V-ATPase, respectively (Kornak et al., 2000, 2001; Segovia-
Silvestre et al., 2009; Tolar et al., 2004), leave the osteoclasts with a
dysfunctional resorption apparatus (Bollerslev et al., 1993; Neutzsky-
Wulff et al., 2008; Ogbureke et al., 2005; Segovia-Silvestre et al., 2009). In
osteopetrosis caused by mutations in either of these proteins in humans,
uncoupling is apparent, in that bone formation is normal or even
increased in the face of lowor absent bone resorption (Alatalo et al., 2004;
Bollerslev et al., 1989; Del Fattore et al., 2006; Karsdal et al., 2007).
Osteoclastsneedboth functional ClC-7andV-ATPase inorder toacidify
the underlying resorption lacuna, which is a crucial part of the bone
resorption process (Frattini et al., 2000, 2003; Henriksen et al., 2004;
Kornak et al., 2000, 2001; Neutzsky-Wulff et al., 2008). In this study we
used a geneticallymodiﬁedmouse strainwith a deletion in Clcn7, in order
to characterize the effects on bone when the osteoclast acidiﬁcation
apparatus is non-functional (Kornak et al., 2001; Neutzsky-Wulff et al.,
2008). ClC-7 deﬁcientmice display a severe osteopetrotic phenotypewith
high bone mineral content, short stature, no eruption of incisors, limited
bonemarrow space and splenomegaly (Kornak et al., 2001) and die at 6–
7 weeks of age as a consequence of the severe phenotype (Kasper et al.,
2005; Kornak et al., 2001). However, the phenotype of ClC-7 deﬁcient
micehasnotbeen fullydescribed,particularlywith respect to theeffects of
the osteoclast defect on subsequent bone formation during bone
remodeling. In addition, an osteopetrorickets phenotype was recently
described in oc/ocmice (lacking the a3 subunit of theV-ATPase) (Schinke
et al., 2009), and it was of interest to investigate whether the same was
true for the ClC-7 deﬁcient mice.
The aim of this study was to describe the development of the
osteopetrotic phenotype and the bone remodeling process in ClC-7
deﬁcient mice by bone histomorphometry. Embryonic ossiﬁcation was
completely normal until high amounts of mineralized cartilage appeared
at E17.5, after which the inability of the ClC-7 deﬁcient osteoclasts to
resorb the mineralized cartilage resulted in accumulation of mineralized
cartilage remnantswithin the developing bones. A clear osteopetrorickets
phenotype was not observed in ClC-7 deﬁcient mice. Dynamic histomor-
phometry revealed low bone formation rates in the ClC-7 deﬁcient mice;
however, bone mineralization was shown to be high, and large regional
differences in bone formation levels were observed. Osteoclast numbers
were shown to be high, and giant osteoclasts were found to occupymost
of the bone marrow space in ClC-7 deﬁcient mice.Materials and methods
Mice
The genetically engineered ClC-7 mouse strain was kindly provided
by Thomas Jentsch (FMP/MDC, Berlin, Germany). Themouse strainwas
generated by deletion of exons 3–7 in the Clcn7 gene (construct C7A) as
describedbyKornak et al. (2001). Prior toexperiments, themouse strain
was backcrossedN5 times to C57BL/6.
Pups were given soft diet (Dough diet for transgenic mice (BioServ)
mixed 1:1 with Solid Drink (Triple A Trading)) each day from P17 until
sacriﬁce. After weaning at P20, the pupswere placed in heated cages. The
mice were genotyped and sacriﬁced at 4–5 weeks of age. Intraperitoneal
injections of calcein (20 mg/kg)were given 6 and2 days prior to sacriﬁce.
ClC-7 KO pups and healthy littermates (ClC-7+/+ or ClC-7+/−) were
used in all experiments.
For histomorphometry studies the following number of animals
were included: ClC-7+/+: 8 males and 8 females, ClC-7+/−:
8 males and 8 females, ClC-7 −/−: 6 males and 4 females.
All experiments conformed to the animal protection laws of Denmark.
Histomorphometry and staining of plastic embedded specimens
Femur length (from femoral head to distal condyles) and femur
width (at midpoint of femoral shaft) were measured with Scion Image
from contact X-rays taken by Faxitron (Sims et al., 2000). For plastic
embedding, the hind legs were ﬁxed in 3.7% formaldehyde in PBS and
stored in 70%ethanol. Tibiaswere embedded inmethylmethacrylate in a
fully calciﬁed state aspreviouslydescribed(Simset al., 2000). Sectionsof
5 μm thickness were cut, and stained with each of the following:
Toluidine blue, Safranin O/Fast Green, Goldners's trichrome, Xylenol
Orange (counterstain for calcein labeled specimens) and TRACP stain.
For growth plate measurement a combined von Kossa/Safranin O/Fast
Green stainingwas applied and the sectionswere analyzed by theKS400
software (Zeiss). Histomorphometry was carried out according to
standard procedures (Parﬁtt et al., 1987) in the proximal tibia using
the Osteomeasure system (OsteoMetrics Inc.). Normal histomorpho-
metric measurements of the secondary spongiosa were performed on
Toluidine blue stained sections 370μm from the end of the hypertrophic
zone of the growth plate in ClC-7+/+ and ClC-7++/− sections, and
740 μm from the growth plate in ClC-7−/− sections to allow for the
extended primary spongiosa in these mice. Cartilage volume was
measured on Safranin O/Fast Green stained sections as previously
described (Simset al., 2005) in the same regionsas for the Toluidineblue
sections. Calculations ofmineral apposition rate (MAR)were based only
on measurements of doubled labeled surfaces (dLS), which were
measured 370μm from the growth plate in ClC-7+/+ and ClC-7+/−
sections, and 1.11 mm from the growth plate in ClC-7−/− sections to
allow for the extended region of woven bone deposition in these mice.
All analyseswereperformed further fromthegrowthplate in ClC-7−/−
bones so that bone undergoing remodeling could be assessed.
Bone mineral density measurements by pQCT
Bone mineral density (BMD) was measured in a STRATEC XCT-
Research SA PQCT machine. Threshold was set to 280 mg/cm2. BMD
was measured in the sub-metaphyseal area below the growth plate.
Parafﬁn embedded specimens
Specimens for parafﬁn embedding were ﬁxed in 3.7% formaldehyde
in PBS, decalciﬁed in 15% EDTA, dehydrated and embedded in parafﬁn.
Embryonic specimens were embedded without prior decalciﬁcation.
Sections of 5 μmthicknesswere cut. Sections frompostnatal boneswere
stained with Alcian Blue (Neutzsky-Wulff et al., 2008), and embryonic
sections were stained by von Kossa and Goldner's trichrome.
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rabbit anti-humanMMP-9 (Nielsen et al., 1997) (kind gift from Dr. B. S.
Nielsen and Dr. N. Borregaard, Finsen Laboratory and Rigshospitalet,
Copenhagen, Denmark), rabbit anti-mouse A3 (kind gift from Thomas
Jentsch, Zentrum für Molekulare Neurobiologie, Hamburg, Germany)
and rabbit anti-rat/mouse AE2 a/b (Frische et al., 2004) (kind gift from
Sebastian Frische, TheWater and Salt Research Center, Faculty of Health
Sciences, University of Århus, Denmark). The EnVision+System Anti-
Rabbit (DAKO) was used as secondary antibody, and visualization was
performed with the DAP Reagent Set (KPL) according to manufactures
protocol.
Digital histographs were captured using an Olympus DP71 digital
cameramounted on an Olympus IX-70 or an Olympus BX-60microscope,
equipped with X10, X20 and X60 objectives.
Statistics
For all measurements of bone histomorphometry, all six groups (2
sexes×3 genotypes) were ﬁrst tested by two-way ANOVA with
Bonferroni post test to identify signiﬁcant differences between sexes
and between genotypes. If there were no signiﬁcant differences between
genders within the individual groups of genotypes, all the data within
each group of genotype was pooled. The pooled data was subsequently
tested by one-way ANOVAwith Dunnett's multiple comparison post test,
to adjust for several tests against the WT group.
For statistical testing between only two different genotypes (data
with normal distribution and equal variance), an unpaired t-test was
used. If the two groups had unequal variance, an unpaired t-test with
Welch's correction was used.
Error bars indicate standard error of mean (SEM). *=pb0.05,
**=pb0.01, ***=pb0.001.
Results
ClC-7 deﬁcient mice display severe osteopetrosis with retarded
longitudinal and radial bone growth
Thebones of ClC-7deﬁcientmicewere examinedbyX-ray, pQCT and
standard bone histomorphometry. The Clcn7−/− mice had a severe
osteopetrotic phenotype including strongly increased BMD (Fig. 1A
and B). In addition the femurs of the Clcn7−/−micewere both shorter
and more narrow than those of theWTmice (Fig. 1C and D), indicating
that both longitudinal and radial bone growth is impaired. A dramatic
increase in trabecular bone volume and trabecular thickness was
observed (Fig. 1E and F), as expected (Kornak et al., 2001; Neutzsky-
Wulff et al., 2008). The heterozygous mice showed no difference to the
WT with regard to BMD, trabecular bone volume or femur length and
width (Fig. 1).
Cartilage mineralization triggers onset of osteopetrotic phenotype during
embryonic development, causing accumulation of cartilage remnants
and defective cortical bone formation
To deﬁne the osteopetrotic phenotype during embryonic devel-
opment we followed ossiﬁcation of the humerus at days E15.5, E16.5
and E17.5 (Fig. 2A). As revealed by von Kossa staining no signiﬁcant
mineralization of hypertrophic cartilage was present at E15.5 and
E16.5. At these stages no differences between WT and mutant
ossiﬁcation centers and surrounding bone collars were obvious,
indicating normal vascular invasion and removal of hypertrophic
cartilage matrix. In contrast, hypertrophic cartilage and trabecular
bone showed clear mineralization at E17.5. Furthermore, accumula-
tion of calciﬁed cartilage is present from this time point, illustrating
the inability of the ClC-7 deﬁcient osteoclasts to degrade calciﬁed
matrix (Fig. 2A). Examinations of embryonic ClC-7 KO bones at E17.5
furthermore revealed formation of several distinct layers of bonecollars, in comparison with the WT mice (Fig. 2B). The structure of
bones from ClC-7 deﬁcient postnatal mice was strikingly abnormal
(Fig. 2C and D), and the lack of compact cortical bonewas a prominent
feature (Fig. 2C), which could possibly be ascribed to the anomalous
bone collar formation. Another persistent ﬁnding in postnatal animals
was the presence of large amounts of mineralized cartilage remnants
within the trabecular bone (Fig. 2D and E), as shown previously
(Neutzsky-Wulff et al., 2008). No changes in bone morphology or
cartilage content were seen in the heterozygousmice (Fig. 2E and data
not shown). Investigation of the growth plate showed a signiﬁcantly
increased total thickness in ClC-7 KOmice, which could be exclusively
attributed to an extension of the hypertrophic zone (Fig. 2F and G).
Taken together, these data conﬁrm that the osteopetrotic phenotype
can largely be explained by a lack of mineralized cartilage resorption,
which already begins during embryonic development.
Diminished bone formation parameters in the face of ongoing
mineralization in ClC-7 deﬁcient mice
To evaluate how bone formation is affected by the loss of ClC-7,
dynamic bone histomorphometry was conducted. In ClC-7 deﬁcient
mice osteoblasts per bone surface (NOb/BPm), osteoblast surface per
bone surface (ObS/BS), osteoid surface per bone surface (OS/BS) and
osteoid volume per bone volume (OV/BV) were all markedly reduced
(Fig. 3A and B, and data not shown). In addition, mineral apposition
rate (MAR) was signiﬁcantly reduced in ClC-7 KO mice (Fig. 3D).
Heterozygous mice showed slightly reduced bone formation para-
meters (Fig. 3A and B and data not shown), but these differences were
not signiﬁcant, and MAR in heterozygous mice was equal to the level
in WT mice (Fig. 3D).
From examination of the calcein labeled surfaces of the ClC-7 KO
bones, it was evident that mineralization does indeed take place in
these mice (Fig. 3E). Calcein labeled almost all surfaces of the
trabecular network in the shaft area of the ClC-7 deﬁcient mice, which
shows that mineralization had taken place during the time of the
calcein injections. Surprisingly, double labeled surfaces per bone
surface (dLS/BS) were markedly reduced (Fig. 3C), indicating few
areas of bone matrix accrual. When, however, the amount of total
calcein labeled surfaces is considered, overall more mineralization
may have taken place in the ClC-7 KO mice during the time of calcein
administration compared to WT mice (Fig. 3E). However, high levels
of singled labeled surfaces are also related to the impairment of bone
resorption, which would lead to increased retention of calcein labels
within the matrix.
Moreover, closer investigation of the tibia revealed great regional
differences in bone formation. In the middle of the shaft towards the
distal end of the tibia, areas with larger patches of osteoid were
observed (Fig. 3F), in contrast to the area which was used for
histomorphological scorings, in which osteoid was scarce (Fig. 3F). In
addition, the averages of osteoid thickness (OTh) in ClC-7 KO mice
(measured in the histomorphometry scoring region) had a very broad
range [0–6.15 μm] in comparison to the WT [1.92–4.10 μm], which
underlines the abnormal bone turnover in ClC-7 KO mice.
Presence of abnormally large osteoclasts in marrow cavity of ClC-7
deﬁcient mice
When examining the bone marrow of the ClC-7 deﬁcient mice, it
was apparent that the marrow was greatly altered compared to WT
mice (Fig. 2B and C). An indeﬁnable cellular mass, which appeared to
be very large multinucleated cellular structures with attachments to
bone, was ﬁlling up the marrow cavity throughout all samples from
the ClC-7 deﬁcient mice (Fig. 4A). As these cellular structures had
resemblance to osteoclasts due to theirmultinucleated nature, scoring
of osteoclasts within ClC-7 KO mice was difﬁcult. Therefore, only
osteoclasts with classical osteoclast morphology and well-deﬁned
Fig. 1. Severe osteopetrosis in ClC-7 deﬁcient mice with retarded longitudinal and radial growth. Littermates from several litters exhibiting the three different genotypes were
selected and sacriﬁced at 4 weeks of age. Hind legs were dissected and ﬁxed in 4% formaldehyde followed by ethanol ﬁxation. Tibias were plastic embedded and sectioned for
histomorphometry. For C–F: Each genotype group contained the following number of animals [+/+]: 16, [+/−]: 16, [−/−]: 10. A) X-ray of hind legs. B) BMDmeasured by pQCT in
sub-metaphyseal region. Number of animals analyzed: [+/+]: 5, [−/−]: 4. C) Measurement of femur length from X-ray images. D) Measurements of femur width from X-ray
images. E) Trabecular bone content (BV/TV) scored by histomorphometry. F) Trabecular thickness (Tb. Th) scored by histomorphometry. ***=pb0.001.
1004 A.V. Neutzsky-Wulff et al. / Developmental Biology 344 (2010) 1001–1010boundaries were counted. In Fig. 4A (right picture), classical
osteoclasts are outlined in blue, and the multinucleated cellular
mass is indicated with red dots.
It was found that ClC-7 KO mice had signiﬁcantly fewer classical
osteoclasts per bone surface compared to WT and heterozygous mice
(Fig. 4B). However, as the bone surface in the ClC-7 KOmicewas greater
than for the WT and the heterozygous mice, the overall number of
classical osteoclasts was signiﬁcantly increased by 125% in the KOmice
compared to WT, which was reﬂected in the parameter: number of
osteoclasts per total volume (NOc/TV) (Fig. 4C). Furthermore, the
classical looking osteoclasts within the ClC-7 KOmicewere signiﬁcantly
reduced in size by 15% compared to WT mice (data not shown).
We then set out to identify the nature of the other multinucleated
cellular structures within the bones of the ClC-7 KOmice. As osteoclasts
are normally the onlymultinucleated cell typewith attachment to bone
surfaces, it wasﬁrst determinedwhether the very large cells in the bone
marrow were abnormal osteoclasts. Positive histological and immuno-histochemical staining of TRACP activity, MMP-9, the a3 subunit of the
v-ATPase, as well as AE2 (chloride/carbonate exchanger located in the
basolateral membrane of osteoclasts (Teti et al., 1989)), all conﬁrmed
that these cellswere indeed osteoclasts (Fig. 4E). Immunohistochemical
staining of both a3 and AE2 furthermore revealed a polarized nature of
the abnormal osteoclasts in theClC-7KObones, as both a3andAE2were
found only inwell-deﬁned areas of the cell membrane corresponding to
the apical and basolateral membrane (Fig. 4E and at higher magniﬁca-
tion in Fig. 4F). These abnormal osteoclasts were not observed inWT or
heterozygous mice (Fig. 4E and data not shown).
When scoring all osteoclast surfaces, including the giant osteoclasts,
it was found that as much as 80% of the trabecular bone surfaces were
covered with either classical or giant osteoclasts in the ClC-7 deﬁcient
mice (Fig. 4D). The ﬁnding of a high number of both classical and
abnormal osteoclasts is in linewithpreviousﬁndings of highly increased
TRACP activity in serum from ClC-7 KO mice (Neutzsky-Wulff et al.,
2008), as well as ﬁndings of high numbers of enlarged osteoclasts in
Fig. 2. Lack of cortical bone structure, extensive cartilage remnants and extended growth plate due to reduced resorption of mineralized cartilage in ClC-7 KO bones. A) Undecalciﬁed
humerus sections of embryos at day E15.5, E16.5 and E17.5 stained with von Kossa and Goldner's trichrome. At day E15.5 and E16.5 no differences between WT and KO can be
observed. Note that at E16.5 only the normally shaped bone collar has become mineralized. At day E17.5 the hypertrophic cartilage shows von Kossa-positive mineralization. This
coincides with the onset of the osteopetrotic phenotype that renders trabecular as well as cortical bone abnormal. B) Undecalciﬁed humerus from prenatal ClC-7 WT and KO mouse
stained Von Kossa and Goldner's trichrome at day E17.5. C) Goldner's trichrome stained cortical bone in the tibial shaft of 4–5 weeks old mice (plastic sections). D) Representative
pictures of Alcian blue staining of cartilage in vertebra of 4–5 weeks old mice (parafﬁn sections). E) Measurement of cartilage volume per bone volume (CtgV/BV) in tibia by
histomorphometry. Each genotype group contained the following number of animals [+/+]: 16, [+/−]: 16, [−/−]: 10. F) Safranin O/von Kossa/Goldner's trichrome staining of
growth plate from 4 weeks old animals. G) Growth plate measurements in tibiae of 4 weeks old animals. Each genotype group contained the following number of animals [+/+]: 5,
[−/−]: 5. The growth plate is signiﬁcantly thickened, but this effect is only due to an extension of the hypertrophic zone. Scale bar=200 μm. *=pb0.05, **=pb0.01, ***=pb0.001.
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Fig. 3. Decreased bone formation parameters despite continued bone mineralization and large regional differences for osteoid deposition. Littermates from several litters exhibiting
the three different genotypeswere selected and sacriﬁced at 4 weeks of age. Tibiae were dissected, plastic embedded, sectioned and stained. For A–D: Each genotype group contained
the following number of animals [+/+]: 16, [+/−]: 16, [−/−]: 10. A) Scoring of osteoblasts (ObS/BS) by histomorphometry. B) Scoring of osteoid volume per bone volume (OV/
BV) by histomorphometry. C) Scoring of double labeled surfaces per bone surface (dLS/BS). D) Calculated mineral apposition rate (MAR). E) Representative pictures of calcein
labeled bones counterstained with Xylenol Orange. F) Goldner's trichrome stain of osteoid in different regions of a ClC-7 KO tibia. White arrows indicate areas with osteoid (stained
red). Scale bar=200 μm. ***=pb0.001.
1006 A.V. Neutzsky-Wulff et al. / Developmental Biology 344 (2010) 1001–1010Autosomal Dominant Osteopetrosis type II (ADOII) patients (Alatalo
et al., 2004; Bollerslev et al., 1993).
Discussion
Astrikingdevelopmental bonephenotypewasdisplayed in theClC-7
KOmice, featuring retarded longitudinal and radial bone growth aswell
as expanded hypertrophic zone in the growth plate. These mice
displayed a highly increased trabecular bone volume and BMD, which
accords with ﬁndings in human osteopetrotic patients (Grodum et al.,
1995; Kaste et al., 2007;Waguespack et al., 2007). In the bones of ClC-7
KO mice large amounts of mineralized cartilage remnants were found,
characteristic of osteopetrotic mouse and patient bone specimens
(Everts et al., 2009; Gil-Henn et al., 2007; Helfrich, 2003; Tolar et al.,
2004), and consistentwith faulty endochondral ossiﬁcation. These signs
of a developmental bone phenotype can in all cases be ascribed to the
dysfunctional osteoclasts, as functional osteoclasts are requisite for bothlongitudinal and radial bone growth (Price et al., 1994), as well as for
removal of mineralized cartilage remnants (Schenk et al., 1967; Shibata
et al., 1997). The resulting high content of mineralized cartilage within
the KO bones might dramatically alter the normal cell behavior of both
osteoclasts and osteoblasts, which is very likely to contribute to some of
the observed ﬁndings in the ClC-7 deﬁcient mice. The high volume of
cartilage remnants within the bones, can also explain the discrepancy
between the increases in trabecular bone volume and BMD. Trabecular
bone volume is increased nearly 900% in ClC-7 deﬁcient mice (Fig. 1E)
whereas trabecular BMDonly showed an increase of 250% in thesemice
(Fig. 1B), which is likely due to the lower mineral content in cartilage
compared to bone matrix.
It is well established that bones of human osteopetrotic patients,
caused by ClC-7 mutations, are fragile and prone to fractures (Del
Fattore et al., 2006;Waguespack et al., 2007), and this increased fragility
is likely, in part, caused by the high cartilage content within the bones.
The strengthof ClC-7KOboneswere not examined directly, but a higher
Fig. 4. Gigantic osteoclasts ﬁll up the bone marrow of ClC-7 deﬁcient mice. Littermates from several litters exhibiting the three different genotypes were selected and sacriﬁced at 4–
5 weeks of age. Tibiae and femora were dissected and embedded in either plastic or parafﬁn and subsequently sectioned and stained. For B–D: Each genotype group contained the
following number of animals [+/+]: 16, [+/−]: 16, [−/−]: 10. Scorings were performed on toluidine blue stained plastic sections. A) Toluidine stained cells in ClC-7 KO bones. Left
picture: Unmodiﬁed image. Right picture: Modiﬁed version of left picture. Bone is outlined in black. Classical osteoclasts are outlined in blue. Area with red dots=multinucleated
cellular mass. B) Scoring of classical osteoclast surface per bone surface (OcS/BS). C) Scoring of total number of classical osteoclasts per total volume (NOc/TV). D) Scoring of classical
osteoclast surface plus cell surface of abnormal osteoclasts per bone surface (OcS/BS). E) Representative pictures of WT and KO bones stained for: TRACP enzyme activity (plastic
sections) (insert=high magniﬁcation), MMP-9 (parafﬁn sections), a3 (parafﬁn section), and AE2 (parafﬁn section). For WT sections, osteoclast-rich areas close to the growth plate
were chosen. F) High magniﬁcation pictures of large abnormal osteoclasts in ClC-7 KO bones stained for either a3 or AE2. Scale bar=100 μm. ***=pb0.001.
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humans, due to the high cartilage content aswell as lack of replacement
of older bone matrix.
Formation of the initial bone collar by intramembraneous ossiﬁca-
tion appeared to be normal in the ClC-7 deﬁcient mice (Fig. 2A, middle
panel), indicating that intramembraneous ossiﬁcation is not affected by
the lack of ClC-7. However, because of the non-functional osteoclasts,
this bone collar cannot be modeled and expanded as it normally occurs
during bone development. To compensate for this, the ClC-7 deﬁcient
mice apparently form several distinct layers of bone collars, as the bones
grow wider (Fig. 2B). During bone growth, the bone matrix of the
individual bone collars will therefore become a part of the trabecular
bone compartment. The trabecular bone compartment will thereforecomprise bone matrix derived from both endochondral and intramem-
braneous ossiﬁcation, which could affect the bone phenotype. This
phenomenon with formation of several distinct bone collars, which
cannot bemodeled or remodeled, is likely the explanation for the lack of
normal compact cortical bone development in ClC-7 deﬁcient mice
(Fig. 2C).
The ClC-7 deﬁcient mice lack a proper bone marrow cavity, but
limitedmarrow space is still present. This space ismost likely developed
during endochondral ossiﬁcation, duringwhichunmineralized cartilage
is degraded by perivascular and endothelial cells (Schenk et al., 1967)
and migrating osteoclasts who utilize matrix metalloproteinases
(MMPs) rather than their acidiﬁcation-dependent resorptivemachinery
(Blavier and Delaisse, 1995; Engsig et al., 2000). Indeed, prior in vitro
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osteoclasts with defective acidiﬁcation (Henriksen et al., 2006;
Neutzsky-Wulff et al., 2008).
A high overall number of osteoclasts was found in this study, in line
with several previous studies of osteopetrotic bones deriving from both
humans and mice (Amling et al., 2000; Bollerslev et al., 1993; Boyce
et al., 1992; Del Fattore et al., 2006; Everts et al., 2009; Gil-Henn et al.,
2007; Helfrich, 2003; Marzia et al., 2000); however, a novel ﬁndingwas
the presence of abnormal large osteoclasts which take up most of the
bone marrow space in the ClC-7 KO mice (Fig. 4E and F). Large
osteoclasts have also been found in in vitro and/or in vivo in studies of
osteopetrotic patients or mouse models, however osteoclasts in those
studies were still clearly identiﬁable as classical osteoclasts (Bollerslev
et al., 1993; Boyce et al., 1992; Walker et al., 2008), in contrast to the
abnormal large osteoclasts identiﬁed in the present work. To our
knowledge, no prior descriptions have been made of the presence of
these very large, abnormal osteoclasts in osteopetrotic models. A
hypothesis could be that the cell fate of the ClC-7 KO osteoclasts has
been altered, leading to fusion into abnormal large osteoclasts, instead
of undergoing apoptosis which would be the normal fate for resorbing
osteoclasts (Manolagas, 2000), as outlined in the hypothetical model in
Fig. 5. A study has shown that apoptotic factors are released during
resorption of the inorganic bone phase and that these factors thereby
control the lifespan of the osteoclasts (Nielsen et al., 2007) (Fig. 5A).
However, this does not apply to theClC-7 deﬁcient osteoclastswhichare
unable to degrade the inorganic bone matrix (Neutzsky-Wulff et al.,
2008). This could potentially result in osteoclasts with an increased
lifespan, as increased survival of osteoclasts has been observed in vitro
when resorption of the inorganic bonematrix is prohibitedby inhibition
of acidiﬁcation (Nielsen et al., 2007). Continued fusion of osteoclasts
with a longer lifespan, or their precursors, could result in the formation
of the observed gigantic osteoclasts (Fig. 5B).
In ClC-7 deﬁcient mice, the abnormal osteoclasts have at the time of
study (4–5 weeks of age), almost completely ﬁlled the bone marrow
space andhave in that process displaced other cell types normally found
in the bone marrow. This displacement of normal marrow cells,
including osteoblast precursors, may contribute to the diminished
bone formation rate observed in the ClC-7 deﬁcientmice. Therefore, the
diminishedbone formationmarkersperbone surfacemight not relate to
a reduced osteogenic potential of theosteoblasts,whichpreviously haveFig. 5. Hypothetical model: altered cell fate of ClC-7 deﬁcient osteoclasts. Schematic drawing
and formmature bone resorbing osteoclasts. The osteoclast will eventually undergo apoptosi
formmature, but non-resorbing osteoclasts. As no apoptotic factors are released from the bo
huge abnormal multinucleated cells.been shown to be normal in vitro (Neutzsky-Wulff et al., 2008), but
rather thephysical constraints imposedby thevast amounts of boneand
cartilage as well as the abnormal osteoclasts taking up most of the
remaining marrow space.
As evidenced by the high level of calcein single labels (Fig. 3E),
mineralization does occur in ClC-7 KO bones and clearly exceeds the
overall level of mineralization taking place in bones fromWTmice. This
is in direct contrast to the reduced MAR, osteoid deposition and
osteoblast surface measured in the region of interest in the ClC-7 KO
bones.However, since calcein labelswouldundernormal circumstances
be partially removed by resorbing osteoclasts, this would not occur in
ClC-7 KO mice due to defective osteoclasts, causing an artiﬁcially high
amount of single labels. In addition to this, regional differences of bone
formationwere observed in the ClC-7 KObones: some regionswere rich
in osteoid, whereas other regions lacked osteoid formation (Fig. 3F).
Clearly, bone mineralization is ongoing and bone formation is
heterogeneous within the ClC-7 KO model, perhaps reﬂecting different
mechanical requirements of these regions. However, a clear uncoupling
phenotype, with normal or increased bone formation in the face of
impaired bone resorption, is not apparent in this osteopetrotic model.
This contrasts with ﬁndings in human osteopetrotic patients suffering
from ADOII caused by mutations in CLCN7, as these patients show clear
signs of uncoupling between resorption and formation (Alatalo et al.,
2004; Bollerslev et al., 1989). ADOII patients display residual activity of
ClC-7 (∼25%) (see Table 1), which make the osteopetrotic phenotype
less severe (Alatalo et al., 2004; Bollerslev et al., 1989; Cleiren et al.,
2001) than the Clcn7−/−mice described here. Because of the less severe
osteopetrotic phenotype in ADOII patients, these patients, or an
equivalent animal model, might comprise a better model for the study
of the coupling mechanism.
An osteopetrorickets phenotype was recently observed in 2-week-
old oc/ocmice,which lack the a3 subunit of theV-ATPase (Schinke et al.,
2009). This phenotypewas characterizedbygrowth retardation, rachitic
widening of the growth plate, marked hyperosteoidosis and diffuse
mineralization of bone surfaces (Schinke et al., 2009). This phenotype
was shown to be associated with decreased acidiﬁcation in the gut
resulting in low absorption of calcium and subsequent hypocalcemia
(Schinke et al., 2009). ClC-7deﬁcientmice displayed someof these traits
like growth retardation and widening of the hypertrophic zone in the
growth plate. Regional differences in osteoid deposition were observedof cell fates in normal (A) and ClC-7 deﬁcient osteoclasts (B). A) Macrophages will fuse
s, due to the release of apoptotic factors during resorption. B)Macrophages will fuse and
ne matrix, the osteoclasts do not undergo apoptosis as normal, and will instead fuse into
Table 1
Association between ClC-7 genotype and phenotype.
% Functional ClC-7 100% 50% ∼25% 0%
Pathological
phenotype
No No Yes (mild) Yes (severe)
Mouse model Clcn7+/+ Clcn7+/− — Clcn7−/−
Human disorders — (no known disorder) ADOII ARO
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detected in the bones of these mice. In addition, high levels of
mineralization were evident (Fig. 3E), and the mice did not display
hypocalcemia (data not shown), indicating that ClC-7 KO mice do not
display a clear osteopetrorickets phenotype, at least not at the age of 4
weeks.
Findings of this study also suggest that Clcn7 is haplosufﬁcient, as no
apparent bone phenotype is observed in heterozygous ClC-7 mice. This
indicates that half the amount of ClC-7 is sufﬁcient, or alternatively that
elevated transcription of the healthy allele is taking place. The
observation of haplosufﬁciency of Clcn7 is consistent with ﬁndings
that no abnormal bonephenotype has been observed in human subjects
lacking one functional allele of CLCN7 (Cleiren et al., 2001). Pathological
bone phenotypes are only seen in ADOII and Autosomal Recessive
Osteopetrosis (ARO) patients who exhibit approximately 25% and 0%
functional ClC-7 respectively, indicating that pathology is only seen
when functional ClC-7 levels range from approximately 25 to 0%
(Cleiren et al., 2001). In Table 1, the association between the amount of
functional ClC-7 and the pathological phenotype in both humans and
mice is given.
In conclusion, ClC-7 deﬁcient mice display a very severe osteope-
trotic bone phenotype, which derives from non-functional osteoclasts
and affects bone development, as well as bone modeling and
remodeling. In addition, the cell fate of the osteoclasts appears to be
disturbed, leading to fusion of osteoclasts into giant abnormal
osteoclasts which ﬁll up the limited bone marrow space, instead of
undergoing normal apoptosis. The mice also demonstrate low bone
formation parameters, regional differences in bone matrix deposition
but ongoing bone mineralization, signifying that bone formation is also
affected in the ClC-7 KO mice. Low bone formation parameters may,
however, relate to displacement of osteoblast progenitors rather than
altered osteogenic potential. Furthermore, unlike what was recently
described for oc/oc mice, a clear osteopetrorickets phenotype was not
observed in the Clcn7−/−mice.
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